1.Inflammatory Bowel Disease in Asia: The Challenges and Opportunities.
Intestinal Research 2015;13(3):188-190
No abstract available.
Asia*
;
Inflammatory Bowel Diseases*
2.Nutritional concerns in pediatric inflammatory bowel disease.
Korean Journal of Pediatrics 2016;59(6):247-251
The pathophysiology and fundamental etiologic mechanism of inflammatory bowel disease (IBD) is not well understood even though therapeutic regimens and drugs are rapidly evolutionary. IBD has complicated connections with genetic, immunologic, gut microbial, environmental, and nutritional factors. It is not clearly well known to the physicians how to feed, what nutrients are more helpful, and what food to be avoided. This review discusses the issues of growth and important nutritional concerns in the management of IBD in childhood.
Inflammatory Bowel Diseases*
;
Pediatrics
3.Micronutrient deficiencies in inflammatory bowel disease: trivial or crucial?.
Intestinal Research 2016;14(2):109-110
No abstract available.
Inflammatory Bowel Diseases*
;
Micronutrients*
4.Inflammatory bowel disease in Korean.
Korean Journal of Medicine 1999;57(4):661-674
No abstract available.
Inflammatory Bowel Diseases*
5.Is It Safe for Patients with Inflammatory Bowel Disease to Go Abroad?.
Intestinal Research 2012;10(4):400-401
No abstract available.
Humans
;
Inflammatory Bowel Diseases
6.Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease.
Pediatric Gastroenterology, Hepatology & Nutrition 2013;16(2):65-70
Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine. The dose of azathioprine has to be reduced or the therapy has to be discontinued frequently because of drug-induced toxicity. In this review, we discuss monitoring of thiopurines, adverse events, malignant complications and how to use azathioprine safely and usefully.
Azathioprine
;
Inflammatory Bowel Diseases
7.Pivot to Asia: inflammatory bowel disease burden.
Prashant SINGH ; Ashwin ANANTHAKRISHNAN ; Vineet AHUJA
Intestinal Research 2017;15(1):138-141
No abstract available.
Asia*
;
Inflammatory Bowel Diseases*
8.What Are the Major Changes in Korean Inflammatory Bowel Disease Surgery?.
Annals of Coloproctology 2018;34(6):277-279
No abstract available.
Inflammatory Bowel Diseases*
9.The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease
Ana Luiza BIANCARDI ; Leandro Lopes TRONCOSO ; Haroldo Vieira DE MORAES JR ; Cyrla ZALTMAN
Intestinal Research 2019;17(1):153-154
No abstract available.
Humans
;
Inflammatory Bowel Diseases
10.Timing of surgery in inflammatory bowel disease.
Chinese Journal of Gastrointestinal Surgery 2013;16(4):315-318
Surgery is an integral part in the treatment of inflammatory bowel disease. Timely surgery is very necessary and can reduce the risk of postoperative complications. Overemphasizing the importance of medical therapy and prolonged use attempting to evade surgery can not maximize the efficacy of medical treatment, but may miss the optimal chance of surgical treatment. It has already been confirmed that ineffective medical treatment, corticosteroid use, malnutrition and infection are the risk factors of surgical complications and should be avoided. Emergency operation and operation at active stage of IBD also increase the surgical risk. Gastroenterologists should be responsible for the judgment of surgery timing and create surgical conditions for the patients with surgical indications.
Humans
;
Inflammatory Bowel Diseases
;
surgery
Result Analysis
Print
Save
E-mail